ByteDance's drug unit showed an AI-designed IL-17 inhibitor at a Boston conference. The molecule targets interactions pharma called undruggable. Only trials will tell.
Eli Lilly gains attention after strong results, with healthcare momentum and GLP treatment demand shaping market focus.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results